Laura Roca-Alonso
Chief Operating Officer bei E-THERAPEUTICS PLC
Profil
Laura Roca-Alonso is currently the Chief Operating & Business Officer at e-Therapeutics Plc since 2020.
Prior to this, she worked as the VP & Head-Corporate Development at Silence Therapeutics Plc from 2004 to 2019.
She also worked as the Director-Business Development at Gyroscope Therapeutics Ltd.
Dr. Roca-Alonso holds a doctorate degree from Imperial College London, a graduate degree from University College London, and an undergraduate degree from Autonomous University of Barcelona.
Aktive Positionen von Laura Roca-Alonso
| Unternehmen | Position | Beginn |
|---|---|---|
| E-THERAPEUTICS PLC | Chief Operating Officer | 02.04.2020 |
Ehemalige bekannte Positionen von Laura Roca-Alonso
| Unternehmen | Position | Ende |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Corporate Officer/Principal | 01.01.2019 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Laura Roca-Alonso
| Imperial College London | Doctorate Degree |
| University College London | Graduate Degree |
| Autonomous University of Barcelona | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| E-THERAPEUTICS PLC | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Private Unternehmen | 1 |
|---|---|
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
